Using omics and other data, researchers performed network analyses that pointed to interactions between human herpesviruses and other Alzheimer's disease risk factors.
The UK-based Dementia Discovery Fund is investing $1.3M in Immuneering's drug-discovery technology in search of new molecular entities for treating Alzheimer's.
By combining iPSCs, CRISPR gene editing, and transcriptomic approaches, researchers examined the effects of an Alzheimer's disease risk variant on brain cells.
Using large-scale GWAS data, researchers saw shared genetic contributors for ALS and frontotemporal dementia, as well as ALS and progressive supranuclear palsy.
The collaborators aim to show that Cytox' VariaTect SNP profiling array and an associated algorithm can effectively predict the presence of Alzheimer's pathology.
Funded projects will will take advantage of molecular platforms that enable large-scale, robust, and reproducible analysis of transcriptional, epigenomic, proteomic, and metabolomic states.
